Home/Healthcare/Biotechnology/Global Precision Neurology Market

Global Precision Neurology Market - Strategic Insights and Forecasts (2026-2035)

Market Size, Share, Forecasts and Trends Analysis By Therapy Type (Small Molecule Therapies, Monoclonal Antibody Therapies, Antisense Oligonucleotide Therapies, Gene Therapies, RNA-Based Therapies, Cell-Based Therapies), By Indication (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Epilepsy, Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Huntington's Disease, Rare Neurological Disorders), By Route of Administration (Oral, Intravenous, Intrathecal, Subcutaneous, Intramuscular), By End User (Hospitals, Specialty Neurology Clinics, Academic and Research Institutes, Diagnostic Laboratories), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography

Market Size in 2026
USD 28.8 billion
Market Size in 2035
USD 114.3 billion
CAGR
14.8%
Study Period
2021-2035
$3,950
Single User License
Access Full Insights
Download Free Sample
Report OverviewSegmentationTable of ContentsCustomize Report

Request Customization

Tell us your specific requirements and we will customize this report for you.

📞

Your data is secure. We do not share information with any third party.

Navigate

Need Assistance?

Our research team is available to answer your questions.

Contact Us
Report IDKSI-008774
PublishedJun 2026
Pages156
FormatPDF, Excel, PPT, Dashboard
Frequently Asked Questions

The global precision neurology market is projected to grow at a CAGR of 14.8%, reaching USD 114.3 billion by 2035 from USD 28.8 billion in 2026.

Major growth drivers include increasing prevalence of neurodegenerative diseases, expanding use of biomarker-guided therapies, rising adoption of genetic testing, growth in RNA therapeutics and gene therapy development, and regulatory support for innovative neurological treatments.

Key restraints include high development costs, lengthy neurological clinical trials, limited access to advanced diagnostic infrastructure, reimbursement uncertainty for premium-priced therapies, and manufacturing complexity for advanced biologics and gene therapies.

North America leads due to strong neuroscience investment, advanced diagnostic infrastructure, favorable reimbursement systems, regulatory support from the FDA, and widespread clinical trial activity in neurodegenerative diseases.

Key companies include Biogen, Eli Lilly and Company, Roche, Novartis, and Ionis Pharmaceuticals.

Need data specifically for your business?Request Custom Research →

Trusted by the world's leading organizations

Weber Shandwick
veolia
Tri
tls
TeamViewer
GE Healthcare
Intel
Proctor and Gamble
ABB
Elkem
Defense Logistics Agency
Amazon